Short answer
Cartesian Therapeutics, Inc. (RNAC) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$11M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$11M
- +68.0% YoY · −172.8% QoQ
- EPS (diluted)
- −$0.38
- +72.5% YoY · −160.3% QoQ
Source: XBRL data from the Cartesian Therapeutics, Inc. (RNAC) Q3 2026 10-Q on SEC EDGAR. USD.
Cartesian Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0 vs $0.5M, down 100% YoY, reflecting no grant revenue
- Net loss $11.5M vs $35.9M, operating loss $25.0M vs $21.1M YoY
- R&D $15.6M, up $1.8M, led by Descartes-08 MG at $6.5M vs $5.4M
- Cash, equivalents and restricted cash $124.7M, operating cash use $70.9M for nine months
- Financing provided $69.6M, including $46.0M term-loan proceeds and $22.8M ATM proceeds
- Outlook: continued losses and higher R&D spending, funding runway at least 12 months, additional financing required
Risk Factors
- New dilution risk: equity issuance or Loan Agreement conversions could reduce ownership and depress common-stock price
- New debt-covenant risk: May 2026 K2HV Loan Agreement secured substantially all assets, excluding intellectual property
- Liquidity risk: minimum unrestricted cash requirement equals 80% of lender obligations beginning April 1, 2027
- Commercial risk: $40.0 million trailing three-month net product revenue covenant begins January 1, 2029
- Default risk: K2HV may accelerate obligations after an event of default, potentially exceeding available cash
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cartesian Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.